PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization
  • Further expands service offering to pharma and biotech customers
  • Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry
  • Adds highly complementary services for the company's fastest growing end market
  • Offers both meaningful cost and revenue synergies which will further accelerate growth
  • Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)ยน after close

Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher"), the world leader in serving science, and PPD, Inc. (Nasdaq: PPD) ("PPD"), a leading global provider of clinical research services to the pharma and biotech industry, today announced that their boards of directors have approved a definitive agreement under which Thermo Fisher will acquire PPD for $47.50 per share for a total cash purchase price of $17.4 billion plus the assumption of approximately $3.5 billion of net debt. This represents a premium of approximately 24% to the unaffected closing price of PPD's common stock on the Nasdaq as of Tuesday, April 13, 2021, or 32% to the 60-day VWAP inclusive of that date.

PPD provides a broad range of clinical research and laboratory services to enable customers to accelerate innovation and increase drug development productivity. A leader in the growing $50 billion clinical research services industry, PPD has more than 26,000 colleagues operating in nearly 50 countries. In 2020, the company generated revenue of $4.7 billion. Upon close of the transaction, PPD will bec…

Read More...
Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization

Articles